ENCell Co., Ltd.
Founded in 2018 and listed on the KOSDAQ in 2024, ENCell is a cell and gene therapy CDMO and next-generation mesenchymal stem cell drug developer.
As of 2026-10-10, ENCell Co., Ltd. has 37 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).
Price
Change
Market cap
Products & technology
- EN001-CMTCharcot-Marie-Tooth disease therapy (next-gen mesenchymal stem cell therapy)
- EN001-DMDDuchenne muscular dystrophy therapy (next-gen mesenchymal stem cell therapy)
- EN001-SPSarcopenia therapy (next-gen mesenchymal stem cell therapy)
- Advanced biopharmaceutical CDMO serviceContract development and manufacturing for cell therapy, organoid-based therapy, and gene therapy
Regulatory approvals
1 Orphan Drug designations · 2022
- Orphan1. 주성분: 동종탯줄유래중간엽줄기세포 (5.0x10^6), 2. 현탁화제: 동결보존배지 (10mL)2022-05-27Orphan Drug designation · in development20220087792
Clinical trials
data.go.kr5 MFDS clinical trial authorisations · 2021–2024 (Phase 1/2 2 · Phase 1 2 · Phase 1/2a 1)
- Phase 1/2aEN0012024-06-27
1 trial site
- Phase 1/2EN0012023-09-19
1 trial site
- Phase 1/2EN0012023-06-22
5 trial sites
- Phase 1EN0012021-06-29
1 trial site
- Phase 1EN0012021-05-04
1 trial site
Global clinical trials
ClinicalTrials.gov · sponsor-matchedPhase 1/2 · Not yet recruiting · 2027-03 · NCT07808905
Phase 1/2 · Recruiting · 2024-05 · NCT06328712
Phase 1/2 · Unknown · 2024-03 · NCT06328725
Phase 1 · Completed · 2022-02 · NCT05333406
Phase 1 · Completed · 2022-01 · NCT05338099
R&D and key agreements
Source: DART corporate disclosureEN001-CMT · 샤르코-마리-투스병(CMT) · 임상2상 진행 예정(조건부허가 신청 계획) · Designated an orphan drug in development in April 2022.
EN001-DMD · 듀센 근디스트로피(DMD) · 임상2상 진행 예정(조건부허가 신청 계획) · Designated an orphan drug in development in May 2022.
조직특이 타게팅 AAV 플랫폼 · 비임상 검증 후 라이선싱 추진 · Developing a tissue-specific targeted AAV platform, including a muscle-targeting AAV platform, to be validated preclinically and then licensed out.
Key disclosures
KRX KIND via OpenDARTShow 5 more events
Publications
PubMed · affiliation-matched- Exploring the Potential of Wharton's Jelly-Derived Mesenchymal Stem Cells as a Therapeutic Approach for Preterm Premature Rupture of Membranes.
International journal of stem cells · 2026-05 · Kim H, Kim H, Jeon S 외 6
- Identification of non-toxic AAV capsid variants with enhanced deep retinal transduction and extended distribution following subretinal delivery.
Biochemical and biophysical research communications · 2026-05 · Lim H, Choi S, Jeon YE 외 6
- Predicting Favorable Conditions for the Determination of Initial Use of Janus Kinase Inhibitors in Patients with Moderate to Severe Atopic Dermatitis.
Journal of clinical medicine · 2025-06 · Park JH, Oh S, Park J 외 2
- Evaluation of AAV transduction efficiency via multiple delivery routes: Insights from peripheral and central nervous system analysis.
Neuroscience · 2025-05 · Lee NK, Na DL, Kim JW 외 5
- Application of Deep Neural Networks in the Manufacturing Process of Mesenchymal Stem Cells Therapeutics.
International journal of stem cells · 2025-05 · Ngo D, Lee J, Kwon SJ 외 3
- Effects of Dexamethasone and Tacrolimus on Mesenchymal Stem Cell Characteristics and Gene Expression.
International journal of stem cells · 2025-05 · Lee NK, Na DL, Myeong SH 외 7
- Prolonged Chronic Cerebral Hypoperfusion Does not Exacerbate Tau Pathology in a Tauopathy Mouse Model.
Journal of integrative neuroscience · 2025-02 · Lee NK, Na DL, Kim HJ 외 4
- Safety and Tolerability of Wharton's Jelly-Derived Mesenchymal Stem Cells for Patients With Duchenne Muscular Dystrophy: A Phase 1 Clinical Study.
Journal of clinical neurology (Seoul, Korea) · 2025-01 · Lee J, Park SE, Kim M 외 5
- Synergistic effect of Wharton's jelly-derived mesenchymal stem cells and insulin on Schwann cell proliferation in Charcot-Marie-Tooth disease type 1A treatment.
Neurobiology of disease · 2024-12 · Oh SJ, Kim H, Park SE 외 6
- Nervonic acid improves fat transplantation by promoting adipogenesis and angiogenesis.
International journal of molecular medicine · 2024-12 · Song JH, Kim SJ, Kwon S 외 6
Show 27 more publications
- Glutaminase-1 inhibition alleviates senescence of Wharton's jelly-derived mesenchymal stem cells via senolysis.
Stem cells translational medicine · 2024-09 · Lee EJ, Kim SJ, Jeon SY 외 8
- Manufacturing Cell and Gene Therapies: Challenges in Clinical Translation.
Annals of laboratory medicine · 2024-07 · Lee NK, Chang JW
- Nervonic Acid Inhibits Replicative Senescence of Human Wharton's Jelly-Derived Mesenchymal Stem Cells.
International journal of stem cells · 2024-02 · Kim SJ, Kwon S, Chung S 외 7
- Anti-necroptotic effects of human Wharton's jelly-derived mesenchymal stem cells in skeletal muscle cell death model via secretion of GRO-α.
PloS one · 2024-01 · Park SE, Kwon SJ, Kim SJ 외 7
- Self-assembled peptide-substance P hydrogels alleviate inflammation and ameliorate the cartilage regeneration in knee osteoarthritis.
Biomaterials research · 2023-05 · Kim SJ, Kim JE, Choe G 외 6
- Iron Oxide Nanoparticle-Incorporated Mesenchymal Stem Cells for Alzheimer's Disease Treatment.
Nano letters · 2023-01 · Jung M, Kim H, Hwang JW 외 12
- A New Method of Myostatin Inhibition in Mice via Oral Administration of Lactobacillus casei Expressing Modified Myostatin Protein, BLS-M22.
International journal of molecular sciences · 2022-08 · Sung DK, Kim H, Park SE 외 6
- Combination of Dexamethasone and Tofacitinib Reduces Xenogeneic MSC-Induced Immune Responses in a Mouse Model of Alzheimer's Disease.
Biomedicines · 2022-08 · Lee NK, Myeong SH, Hwang JW 외 6
- Intracerebroventricular Administration of Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells Induces Transient Inflammation in a Transgenic Mouse Model and Patients with Alzheimer's Disease.
Biomedicines · 2022-02 · Myeong SH, Kim H, Lee NK 외 5
- Wharton's Jelly-Derived Mesenchymal Stem Cells with High Aurora Kinase A Expression Show Improved Proliferation, Migration, and Therapeutic Potential.
Stem cells international · 2022-01 · Kim SJ, Park SE, Jeong JB 외 8
- 2-IPMA Ameliorates PM2.5-Induced Inflammation by Promoting Primary Ciliogenesis in RPE Cells.
Molecules (Basel, Switzerland) · 2021-09 · Choi JY, Bae JE, Kim JB 외 13
- Powerful use of automated prioritization of candidate variants in genetic hearing loss with extreme etiologic heterogeneity.
Scientific reports · 2021-09 · Kim SY, Lee S, Seo GH 외 12
- Wharton's Jelly-Derived Mesenchymal Stem Cells Reduce Fibrosis in a Mouse Model of Duchenne Muscular Dystrophy by Upregulating microRNA 499.
Biomedicines · 2021-08 · Park SE, Jeong JB, Oh SJ 외 9
- Triamterene induces autophagic degradation of lysosome by exacerbating lysosomal integrity.
Archives of pharmacal research · 2021-06 · Park NY, Jo DS, Kim YH 외 10
- Otological aspects of NLRP3-related autoinflammatory disorder focusing on the responsiveness to anakinra.
Rheumatology (Oxford, England) · 2021-03 · Kim BJ, Kim YH, Lee S 외 12
- Comparative Proteomic Analysis of the Mesenchymal Stem Cells Secretome from Adipose, Bone Marrow, Placenta and Wharton's Jelly.
International journal of molecular sciences · 2021-01 · Shin S, Lee J, Kwon Y 외 6
- Immunosuppressant Drugs Mitigate Immune Responses Generated by Human Mesenchymal Stem Cells Transplanted into the Mouse Parenchyma.
Cell transplantation · 2021-01 · Hwang JW, Myeong SH, Lee NH 외 5
- Exposure of Mesenchymal Stem Cells to an Alzheimer's Disease Environment Enhances Therapeutic Effects.
Stem cells international · 2021-01 · Park SE, Kim HS, Kwon SJ 외 7
- Fibulin 5, a human Wharton's jelly-derived mesenchymal stem cells-secreted paracrine factor, attenuates peripheral nervous system myelination defects through the Integrin-RAC1 signaling axis.
Stem cells (Dayton, Ohio) · 2020-10 · Won SY, Kwon S, Jeong HS 외 4
- Ethionamide Preconditioning Enhances the Proliferation and Migration of Human Wharton's Jelly-Derived Mesenchymal Stem Cells.
International journal of molecular sciences · 2020-09 · Lee NH, Myeong SH, Son HJ 외 4
- Pressure Stimuli Improve the Proliferation of Wharton's Jelly-Derived Mesenchymal Stem Cells under Hypoxic Culture Conditions.
International journal of molecular sciences · 2020-09 · Park SE, Kim H, Kwon S 외 5
- Anti-Fibrotic Effect of Human Wharton's Jelly-Derived Mesenchymal Stem Cells on Skeletal Muscle Cells, Mediated by Secretion of MMP-1.
International journal of molecular sciences · 2020-08 · Choi A, Park SE, Jeong JB 외 6
- Exploring the Potential of Mesenchymal Stem Cell-Based Therapy in Mouse Models of Vascular Cognitive Impairment.
International journal of molecular sciences · 2020-08 · Lee NK, Kim H, Chang JW 외 6
- Significant Mendelian genetic contribution to pediatric mild-to-moderate hearing loss and its comprehensive diagnostic approach.
Genetics in medicine : official journal of the American College of Medical Genetics · 2020-06 · Kim BJ, Oh DY, Han JH 외 16
- Recovery of Tendon Characteristics by Inhibition of Aberrant Differentiation of Tendon-Derived Stem Cells from Degenerative Tendinopathy.
International journal of molecular sciences · 2020-04 · Kim SJ, Oh HW, Chang JW 외 1
- A Comparison of Immune Responses Exerted Following Syngeneic, Allogeneic, and Xenogeneic Transplantation of Mesenchymal Stem Cells into the Mouse Brain.
International journal of molecular sciences · 2020-04 · Hwang JW, Lee NK, Yang JH 외 4
- Cerebrospinal fluid from Alzheimer's disease patients as an optimal formulation for therapeutic application of mesenchymal stem cells in Alzheimer's disease.
Scientific reports · 2019-01 · Lee J, Kwon SJ, Kim JH 외 6
Patents
KIPRIS · applicant-matchedPublished · 2025-12 · Application 1020250196299
Published · 2025-07 · Application 1020250099298
Published · 2025-05 · Application 1020250067083
PCT · Published · 2025-05 · Application PCT/KR2025/006978
PCT · Published · 2025-04 · Application PCT/KR2025/005000
PCT · Published · 2025-03 · Application PCT/KR2025/003987
- PEPTIDE TARGETING OCULAR CELLS OR TISSUES, AND VIRAL CAPSID PROTEIN AND VIRAL VECTOR COMPRISING SAME
PCT · Published · 2025-03 · Application PCT/KR2025/003613
Registered · 2025-01 · Application 1020250009114
PCT · Published · 2024-12 · Application PCT/KR2024/019545
Published · 2024-12 · Application 1020240177189
Show 48 more patents
Published · 2024-03 · Application 1020240043116
PCT · Published · 2024-03 · Application PCT/KR2024/003186
EP · Published · 2024-02 · Application 24760611.4
EP · Published · 2024-02 · Application 24760612.2
PCT · Published · 2024-02 · Application PCT/KR2024/002374
PCT · Published · 2024-02 · Application PCT/KR2024/002372
PCT · Published · 2024-02 · Application PCT/KR2024/002377
PCT · Published · 2024-02 · Application PCT/KR2024/002328
Published · 2024-02 · Application 1020240025640
PCT · Published · 2024-02 · Application PCT/KR2024/001564
PCT · Published · 2024-02 · Application PCT/KR2024/001561
Withdrawn · 2024-02 · Application 1020240015781
Published · 2024-02 · Application 1020240015832
Published · 2023-06 · Application 1020230072375
Registered · 2023-06 · Application 1020230071902
Withdrawn · 2023-04 · Application 1020230048087
Rejected · 2023-04 · Application 1020230045495
Published · 2023-03 · Application 1020230027905
Published · 2023-02 · Application 1020230025103
Registered · 2023-02 · Application 1020230025102
Published · 2023-02 · Application 1020230024481
US · Published · 2022-12 · Application 18723656
PCT · Published · 2022-12 · Application PCT/KR2022/021174
Rejected · 2022-04 · Application 1020220045896
Rejected · 2021-12 · Application 1020210186584
US · Published · 2021-11 · Application 18256352
EP · Published · 2021-11 · Application 21903672.0
PCT · Published · 2021-11 · Application PCT/KR2021/017083
Registered · 2021-11 · Application 1020210160705
US · Published · 2021-11 · Application 18036284
US · Published · 2021-11 · Application 18252945
EP · Published · 2021-11 · Application 21892296.1
EP · Published · 2021-11 · Application 21892295.3
PCT · Published · 2021-11 · Application PCT/KR2021/016262
PCT · Published · 2021-11 · Application PCT/KR2021/016277
PCT · Published · 2021-07 · Application PCT/KR2021/009117
US · Published · 2021-04 · Application 17917831
EP · Published · 2021-04 · Application 21784758.1
PCT · Published · 2021-04 · Application PCT/KR2021/004244
EP · Published · 2021-03 · Application 21775209.6
PCT · Published · 2021-03 · Application PCT/KR2021/003583
EP · Registered · 2021-01 · Application 21772334.5
PCT · Published · 2021-01 · Application PCT/KR2021/000941
Registered · 2020-11 · Application 1020200150504
Withdrawn · 2020-07 · Application 1020200093991
Registered · 2020-04 · Application 1020200042893
Registered · 2020-03 · Application 1020200036871
Rejected · 2020-03 · Application 1020200034461
AI reads
MAA server logs · IP-verifiedPulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.
Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.
Collected as raw material for future answers.
Queries from users who connected this index to their own AI.
- OpenAIOAI-SearchBot39
- PerplexityPerplexityBot4
- GoogleGoogleOther2
- AnthropicClaudeBot2
- MicrosoftBingbot1
Measured since Aug 27, 2026 · 5 AI engines · last read Oct 10, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.
Connect this company index directly to your AI
Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for ENCell Co., Ltd. and every listed Korean medical, bio and AI company.
How to connect (MCP)Companies in the same categoryPharma & CDMO
Founded in 1941 and listed on the KOSPI in 1975, Ildong Holdings is the holding company of the Ildong Pharmaceutical Group, overseeing pharmaceutical, aesthetic medical device, and drug development affiliates.
Founded in 1941 and listed on the KOSPI in 1975, Yuyu Pharma is a pharmaceutical company with a co-promotion agreement with Dong-A ST for Tanamin.
Founded and listed on the KOSPI in 2016, Il Dong Pharmaceutical manufactures products including the Aronamin vitamin line.
Founded 2000, KOSDAQ-listed 2009, Medy-Tox develops and exports botulinum toxin biopharmaceuticals including Meditoxin and Innotox.
KOSPI-listed comprehensive pharmaceutical company specializing in blood products and vaccines, with FDA-approved immunoglobulin ALYGLO.
KOSPI-listed pharmaceutical company behind Coldwon cold medicine and Jangdaewon probiotics, developing a P-CAB drug pipeline.
Founded 2011, listed 2016 — Samsung Biologics is a biopharma CDMO with 785,000L capacity across five Songdo plants.
Founded in 2006 and listed on KOSDAQ in 2020, Genolution is a molecular diagnostics and RNAi company producing nucleic acid extraction reagents and devices.
Ahn-Gook Pharmaceutical sells the cough/expectorant drug Sinecuran and the eye-health supplement Tobicom.
Founded in 2003 and listed on KOSDAQ in 2015, Corestem Chemon develops stem cell therapies and provides nonclinical CRO services, including the ALS treatment Neuronata-R.
Founded 2005, KOSDAQ-listed 2022, BIO-FD&C develops plant-cell platform-based cosmeceutical materials and biopharma pipelines.
KOSPI-listed comprehensive pharma company behind Amaryl diabetes drug and the USD 86.25M HL5101 anticancer out-license deal.
Sources and updates
Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- Approvals & clinical trials
- Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
- Key disclosures
- KRX KIND via OpenDART exchange filings — updated daily
- Global clinical trials
- ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
- Financials
- DART corporate disclosure filings — annual
- Publications
- PubMed (US National Library of Medicine) — affiliation-matched, updated daily
- Patents
- KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
- AI reads
- Our server logs, IP-verified every 6 hours
- AI visibility
- Measured 2026-10-01
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition